And caused by high staff costs with no hint why this has increased by 50% this quarter, and last quarter it has already increased by 50%, this can't all be on sales rep??? That is too much for them. These better bring in significant revenue and/or just once-off start-up cost for revenue increase.
I see the worst case is to start again, sell all their commercial products/assets, do a massive staff cut and start again as bio-stock startup with all their focused turned to IMMU to speed the development, using those capitals obtain from the sale as start-up cost, their current MC is already the value of a start-up bio-tech company right now.
Ann: Preliminary Final Report for period to 31 December 2018, page-14
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$9.86 |
Change
-0.140(1.40%) |
Mkt cap ! $209.4M | |||
| Open | High | Low | Value | Volume |
| $10.00 | $10.00 | $9.65 | $69.04K | 7.028K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 60 | $10.35 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $9.62 | 1 | 1 |
View Market Depth
| Last trade - 15.59pm 12/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |